Posted On: 06/22/2014 4:53:23 PM
Post# of 82
The best is still to come
Recently, a GW pharmaceuticals product was approved for the treatment of a rare form of epilepsy in children. Great news, for those children and for GW's investors like me. Shareprices are exploding.
But what I am really waiting for, is the approval of Canabidiol as an antipsychotic treatment. That is a HUGE market. Canabidiol is a non-addictive and non-psychoactive component of Cannabis. It seems to work well with few side effects (u like existing antipsychotics). So, in my opinion, the best is still to come. For investors and for schizophrenia patients.
Tom
Recently, a GW pharmaceuticals product was approved for the treatment of a rare form of epilepsy in children. Great news, for those children and for GW's investors like me. Shareprices are exploding.
But what I am really waiting for, is the approval of Canabidiol as an antipsychotic treatment. That is a HUGE market. Canabidiol is a non-addictive and non-psychoactive component of Cannabis. It seems to work well with few side effects (u like existing antipsychotics). So, in my opinion, the best is still to come. For investors and for schizophrenia patients.
Tom
(0)
(0)
